close 76% of retail accounts lose money when trading CFDs with this provider. Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
SearchSearch
Change languageEnglish (International)
Dashboard

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Home・Stock List・Celldex Therapeutics Inc
Search

Celldex Therapeutics Inc

Closed

SectorHealthcare

21.21 4.59

Strong Buy

Price update 13 Jun 2025, 19:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

20.62

Max

21.4

Key metrics

By Trading Economics

Income

-6.7M

-54M

Sales

-480K

695K

EPS

-0.81

Profit margin

-7,740.432

Employees

186

EBITDA

-6.7M

-62M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+169.29% upside

Dividends

By Dow Jones

Next Earnings

6 Aug 2025

Market Stats

By TradingEconomics

Market Cap

28M

1.4B

Previous open

16.62

Previous close

21.21

News Sentiment

By Acuity

50%

50%

177 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

18.91 / 20.63 Support & Resistance

Celldex Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

13 Jun 2025, 22:33 UTC

Acquisitions, Mergers, Takeovers

Millicom to Acquire Telefonica Ecuador for $380 Million

DJ

Read

13 Jun 2025, 23:50 UTC

Acquisitions, Mergers, Takeovers

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

DJ

Read

13 Jun 2025, 23:20 UTC

Acquisitions, Mergers, Takeovers

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

DJ

Read

13 Jun 2025, 23:09 UTC

Acquisitions, Mergers, Takeovers

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

DJ

Read

13 Jun 2025, 23:03 UTC

Acquisitions, Mergers, Takeovers

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

DJ

Read

13 Jun 2025, 22:18 UTC

Acquisitions, Mergers, Takeovers

Millicom to Acquire Telefonica Ecuador for $380M

DJ

Read

13 Jun 2025, 22:04 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Better Data Facilitate Investments In Oil Patch -- Market Talk

DJ

Read

13 Jun 2025, 21:42 UTC

Acquisitions, Mergers, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

DJ

Read

13 Jun 2025, 21:35 UTC

Acquisitions, Mergers, Takeovers

Bunge: Outside Date Extended to July 3

DJ

Read

13 Jun 2025, 21:35 UTC

Acquisitions, Mergers, Takeovers

Bunge: Subject to Satisfaction of Remaining Conditions, Bunge and Sellers Expect to Complete Transaction July 2

DJ

Read

13 Jun 2025, 21:34 UTC

Acquisitions, Mergers, Takeovers

Bunge Gets Mexico Approval for Viterra Deal

DJ

Read

13 Jun 2025, 21:32 UTC

Acquisitions, Mergers, Takeovers

Bunge Gets China Approval for Viterra Deal

DJ

Read

13 Jun 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Read

13 Jun 2025, 20:45 UTC

Acquisitions, Mergers, Takeovers

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

DJ

Read

13 Jun 2025, 20:34 UTC

Acquisitions, Mergers, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- Update

DJ

Read

13 Jun 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

DJ

Read

13 Jun 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

DJ

Read

13 Jun 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

DJ

Read

13 Jun 2025, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

DJ

Read

13 Jun 2025, 19:12 UTC

Market Talk

Oil Futures Jump As Israel Strikes Iranian Targets -- Market Talk

DJ

Read

13 Jun 2025, 19:04 UTC

Market Talk

Canada Military Spending Hike to Lift Long-Term Yields -- Market Talk

DJ

Read

13 Jun 2025, 18:54 UTC

Market Talk

Correction to Gold Settles Market Talk

DJ

Read

13 Jun 2025, 18:01 UTC

Market Talk

Gold Settles at Record High -- Market Talk

DJ

Read

13 Jun 2025, 17:40 UTC

Market Talk

U.S. Oil Rig Count Falls By 3 to 439 -- Market Talk

DJ

Read

13 Jun 2025, 17:21 UTC

Market Talk

Dollar Index, Commodities Rise -- Market Talk

DJ

Read

13 Jun 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

Advent Proposal Values Spectris at GBP37.63 Per Share, Company Said Monday -- WSJ

DJ

Read

13 Jun 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

KKR Is Preparing a Bid for High-Tech Instrument Maker Spectris, Sources Say -- WSJ

DJ

Read

13 Jun 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

Private-Equity Firm Is Vying With Advent for the U.K. Company, Sources Say -- WSJ

DJ

Read

13 Jun 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

KKR Making Competing Bid for Equipment Maker Spectris -- WSJ

DJ

Read

13 Jun 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

DJ

Read

Peer Comparison

Price change

Celldex Therapeutics Inc Forecast

Price Target

By TipRanks

169.29% upside

12 Months Forecast

Average 57.25 USD  169.29%

High 78 USD

Low 38 USD

Based on 9 Wall Street analysts offering 12 month price targets forCelldex Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

9

Buy

0

Hold

0

Sell

Based on 9 analysts giving stock ratings to Celldex Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

18.91 / 20.63Support & Resistance

Short Term

Weak Bullish Evidence

Recent bullish events outweigh bearish events.

Intermediate Term

Bullish Evidence

Recent bullish events outweigh bearish events.

Long Term

Bearish Evidence

All events are bearish.

Sentiment

By Acuity

177 / 380 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

Other stocks from the sector

LLY

Eli Lilly and Co.

818.58

↑ +0.92%

JNJ

Johnson and Johnson

156.9

↑ +0.22%

ABBV

AbbVie Inc

190.58

↓-0.85%

NVO

Novo Nordisk A-S

79.74

↓-1.64%

UNH

UnitedHealth Group Inc

313.25

↓-1.52%